Remove Communication Remove Information Remove Vaccines
article thumbnail

Q&A: Pharmacist Highlights Challenges in Vaccine Information Navigation Amid Changing Recommendations

Drug Topics

In an interview, Cherokee Layson-Wolf, PharmD, BCACP, FAPhA, professor of practice, sciences, and health outcomes research at the University of Maryland, explored the evolving landscape of vaccine recommendations, emphasizing the critical role pharmacists play in guiding patients through complex medical information.

article thumbnail

Q&A: Expert Highlights Importance of Trusted Sources for Vaccine Information

Drug Topics

In an interview on vaccine recommendations, health care professionals expressed growing concerns about the changing landscape of medical information dissemination. In an interview on vaccine recommendations, health care professionals expressed growing concerns about the changing landscape of medical information dissemination.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Pneumococcal Vaccine Patient Education: What Pharmacists Should Know and Share

Drug Topics

Panelists discuss how pharmacists should educate patients about pneumococcal vaccines by providing current vaccine information statements (VIS) updated May 29, 2025, explaining common adverse effects like injection site reactions and mild systemic symptoms as normal immune responses, conducting thorough pre-vaccination screening for moderate-to-severe (..)

article thumbnail

ACIP Panel Removal Sparks Concerns, Pharmacists Warn of More Vaccine Distrust

Drug Topics

Experts discuss the recent dismissal of all 17 members of the Advisory Committee on Immunization Practices (ACIP), a panel that provides guidance to the CDC on vaccine recommendations. This abrupt change has raised significant concerns within the health care community about the potential impact on vaccine trust and public health policy.

article thumbnail

Bharat Biotech acquires licence for GSK’s Shigella vaccine development

Pharmaceutical Technology

June 13, 2025 Share Copy Link Share on X Share on Linkedin Share on Facebook GSK’s vaccine leverages GMMA technology. GSK has licensed altSonflex1-2-3, its Shigella vaccine candidate, to Bharat Biotech for continued development and distribution in low and middle-income nations. Credit: viewimage/Shutterstock.

article thumbnail

GSK’s world-first gonorrhoea vaccine launched in England

Pharmaceutical Technology

Using real-world data to support vaccine outreach and education Buy Reports Newsletters PT News GSK’s world-first gonorrhoea vaccine launched in England The immunisation programme aims to reduce rising gonorrhoea rates and address antibiotic-resistant strains. GSK’s 4CMenB is not a newly approved vaccine.

article thumbnail

Progress in Dermatology Paves the Way for Vaccine Development

Drug Topics

With significant progress made in researchers’ understanding of dermatological diseases, a pathway has been made for the development of targeted vaccines, according to data published in Vaccines. 5 Throughout the past 10 years, development of vaccines for preventing skin diseases has made significant progress.